Clinical Pharmacology & Biopharmaceutics
Open 91桃色
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open 91桃色 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open 91桃色 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 1089
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Cellular oxidative stress in patients with head and neck cancer in treatment with cisplatin and radiotherapy
3rd International Conference on Clinical Pharmacy
Patricia Moriel
State University of Campinas, Brazil
Posters-Accepted Abstracts: Clin Pharmacol Biopharm
DOI:
Abstract
Cancer is one of the biggest public health problems, especially head and neck cancer, being the fifth most prevalent neoplasia in the World. The most effective treatment for head and neck cancer is radiotherapy along with high doses of cisplatin as chemotherapy, but its use is restricted because of the cisplatin芒�?�?s toxicity, that is caused principally by oxidative stress. This is a primary study, since previous studies on literature evaluated cellular oxidative stress only on animal models. The purpose of this study is to evaluate cellular oxidative stress on patients with head and neck cancer in treatment concomitant with radiotherapy and cisplatin. This is a prospective clinical and observational study at a hospital in Brazil, started in February 2015 and in continuity at the present moment. Before and after five days of the first chemotherapy cycle, blood of patients was collected to study through the MitoSox Red, H2DCF-DA (2 ,7-dichlorofluorescein) and Amplex Red tests to determinate cellular oxidative stress. The tests were done with the blood samples of ten patients before and after first cycle of chemotherapy. MitoSox Red test showed variation from 509.94�?卤303.11 to 495.96�?卤316.00 A.F.U. (p=0.9152); H2DCF-DA test varied from 828.52�?卤315.79 to 1258.93�?卤1241.93 A.F.U. (p=0.3702); and Amplex Red test from 6.63x10-15�?卤7.30x10-15 to 6.09x10-15�?卤5.68x10-15 H202/s (p=0.8334). The tests did not show a significant diference between that realized before and after chemotherapy. It is necessary for a bigger number of patients inclusion.Biography
Patricia Moriel has completed his PhD at the age of 29 years from University of São Paulo (Brazil). She is a professor and director of a research team focusing on pharmacovigilance and pharmacotherapy at University of Campinas, Brazil. In the last year she has published 10 papers in reputed journals.
Email: morielpa@fcm.unicamp.br
